Protagonist Therapeutics (PTGX) Change in Acquisitions & Divestments (2016 - 2026)

Protagonist Therapeutics (PTGX) has 11 years of Change in Acquisitions & Divestments data on file, last reported at $156.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 2137.48% year-over-year to $156.7 million; the trailing twelve-month figure through Mar 2026 stood at $641.5 million (up 148.08% YoY), and the FY2025 full-year result was $491.8 million, up 52.0% from the prior year.
• Change in Acquisitions & Divestments climbed to $156.7 million in Q1 2026, from $153.2 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $331.6 million in Q3 2025 to a low of $7.0 million in Q1 2025.
• A 5-year average of $89.5 million and a median of $76.6 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 90.27% in 2025 and surged 2137.48% in 2026, its largest moves.
• Tracing PTGX's Change in Acquisitions & Divestments over 5 years: stood at $84.6 million in 2022, then sank by 56.62% to $36.7 million in 2023, then surged by 188.81% to $106.0 million in 2024, then surged by 44.57% to $153.2 million in 2025, then climbed by 2.26% to $156.7 million in 2026.
• Business Quant data shows PTGX's Change in Acquisitions & Divestments at $156.7 million in Q1 2026, $153.2 million in Q4 2025, and $331.6 million in Q3 2025.